New treatments for age-related macular degeneration

Age and Ageing

Volumn 36, Issue 1, 2007, Pages 8-10

  Imrie, Fraser R ^a   Bailey, Clare ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; RETINOL; VASCULOTROPIN; ZINC; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ARGON LASER; ARTICLE; BLINDNESS; CLINICAL FEATURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIODE LASER; DRUG APPROVAL; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; DRUSEN; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER COAGULATION; NONHUMAN; NUTRITIONAL HEALTH; OFF LABEL DRUG USE; PATIENT COUNSELING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SMOKING CESSATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION; AGED; AGING; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; PATHOLOGY; PHOTOCHEMOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; AGING; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; HUMANS; LIGHT COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947611657     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afl135     Document Type: Article

References (14)

1. The Age-Related Eye Disease Study Research Group. A randomised, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and visual loss: AREDS Report No. 8. Arch Ophthalmol 2001; 119: 1417-36.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-42.
3. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol 2002; 86: 663-69.
4. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-14.
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with verteporfin: one year results of 2 randomised trials - TAP report 1. Arch Ophthalmol 1999; 117: 1329-45.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials - TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
7. Krzystolik MG, Afshari MA, Adamis AP et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-46.
8. Mordenti H, Cuthebertson RA, Ferrara N et al. Comparisons of the intraocular tissue distribution, pharmacokinetics and safety of 125I labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27: 536-44.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
10. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
11. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
12. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
13. Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab. Retina 2006; 26: 262-69.
14. Korotkin A, Kozak I, Morrison VL, Magana L, Freeman WR. An emerging problem; recurrence of CNV in AMD is common after cessation of 24 month treatment with ranibizumab (Lucentis®). Invest Ophthalmol Vis Sci 2006; 47 E-Abstract 2961.